Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
1.79B
Enterprise Value
1.49B
Income
100.72M
Sales
880.94M
Book/sh
28.57
Cash/sh
11.32
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
1333
IPO
May 03, 2018
P/E
18.07
Forward P/E
40.61
PEG
-
P/S
2.04
P/B
2.17
P/C
5.47
P/FCF
18.31
EV/EBITDA
43.37
EV/Sales
1.70
Quick Ratio
4.61
Current Ratio
6.45
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
3.43
EPS next Y
1.52
EPS next Q
0.92
EPS this Y
-46.25%
EPS next Y
17.18%
EPS next 5Y
-5.45%
EPS past 3/5Y
- -
Sales past 3/5Y
30.77% 51.21%
EPS Y/Y TTM
131.98%
Sales Y/Y TTM
-0.19%
EPS Q/Q
-351.33%
Sales Q/Q
-7.93%
Insider Own
5.72%
Insider Trans
-0.26%
Inst Own
119.06%
Inst Trans
-6.06%
ROA
11.44%
ROE
13.49%
ROIC
11.77%
Gross Margin
86.19%
Oper. Margin
1.79%
Profit Margin
11.43%
SMA20
-8.62%
SMA50
-10.30%
SMA200
7.57%
Trades
Shs Outstand
28.94M
Shs Float
27.31M
52W High
147.03 -57.91%
52W Low
38.91 59.06%
Volatility
3.95% 4.10%
ATR (14)
2.87
RSI (14)
37.12
Beta
0.65
Rel Volume
0.02
Avg Volume
757.03K
Volume
613
Perf Week
-6.97%
Perf Month
-9.08%
Perf Quarter
8.39%
Perf Half Y
45.08%
Perf YTD
-32.90%
Perf Year
-31.92%
Perf 3Y
-50.76%
Perf 5Y
-77.83%
Perf 10Y
-
Prev Close
62.11
Price
61.89
Change %
-0.35%
Consensus
Hold
Avg. Price Target
$69.62
Implied Upside
+12.5%
Analysts14incl. previous ratings
Rating Distribution2 Buy · 9 Hold · 3 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 07, 2026Initiated
BCS logoBBarclays
Underweight$65+5.0%
Aug 04, 2026Upgrade
OPY logoOOppenheimer
Perform → Outperform$85+37.3%
Jul 28, 2026Resumed
UBS logoUUBS
Sell$39-37.0%
Jun 23, 2026Downgrade
EVR logoEEvercore ISI
Outperform → In-line$40-35.4%
May 22, 2026Downgrade
BAC logoBBofA Securities
Neutral → Underperform$39-37.0%
May 05, 2026Downgrade
PPiper Sandler
Overweight → Neutral$55-11.1%
May 05, 2026Downgrade
BAC logoBBofA Securities
Buy → Neutral$53-14.4%
Feb 13, 2026Downgrade
WWolfe Research
Outperform → Peer Perform
Feb 12, 2026Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$70+13.1%
Feb 12, 2026Downgrade
RRobert W. Baird
Outperform → Neutral$74+19.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHN RONDONIOfficerAug 24 '26Proposed Sale62.36643,991Aug 24 04:29 PM
Kelly Jason PSee RemarksAug 07 '26Sale59.5596357,34718,985Aug 11 07:13 PM
JASON P KELLYOfficerAug 07 '26Proposed Sale59.5596357,342Aug 07 04:08 PM
Rondoni JohnSee RemarksMay 15 '26Sale43.282,641114,30227,165May 19 04:05 PM
JOHN RONDONIOfficerMay 15 '26Proposed Sale43.282,641114,304May 15 04:17 PM
Rondoni JohnSee RemarksMay 14 '26Sale43.0170030,10729,806May 15 04:05 PM
JOHN RONDONIOfficerMay 14 '26Proposed Sale43.0170030,106May 14 04:34 PM
mcCormick ShawnDirectorMay 08 '26Sale45.3169631,53627,712May 11 04:05 PM
SHAWN T MCCORMICKDirectorMay 08 '26Proposed Sale45.5769631,717May 08 04:22 PM
Rondoni JohnSee RemarksJan 09 '26Sale100.0010910,90013,797Jan 12 04:05 PM
JOHN RONDONIOfficerJan 09 '26Proposed Sale95.0010910,355Jan 09 04:32 PM
mcCormick ShawnDirectorDec 02 '25Sale139.001,200166,80024,846Dec 04 04:05 PM
SHAWN T MCCORMICKDirectorDec 02 '25Proposed Sale126.341,200151,608Dec 02 04:27 PM
mcCormick ShawnDirectorNov 28 '25Sale127.482,000254,96026,046Dec 01 05:56 PM
SHAWN T MCCORMICKDirectorNov 28 '25Proposed Sale127.332,000254,660Nov 28 01:16 PM
Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The firm offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. It operates through the United States and All Other Countries geographical segments. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.
FounderMr. Timothy P. Herbert
Senior VPMr. Bryan K. Phillips J.D.
Chief Strategy and Growth OfficerMr. Carlton W. Weatherby
Executive VP & CFOMr. Matthew J. Osberg
Chief Operations & Innovation OfficerMr. Jason P. Kelly